Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
What Dr. files
- Others100
- Updates54
- Investor Meet51
- Important41
- Board Meeting9
- PPTs6
Dr. Reddy's Laboratories Limited has informed the Exchange about General Updates
Dr. Reddy's allotted 4,110 new equity shares (Re.1/- each) to employees exercising stock options under its ESOP scheme. This marginally increases total issued share capital to ₹83.46 Cr, reflecting minor dilution for existing shareholders.
Dr. Reddy's formulations facility received a USFDA Form 483 with four observations following a GMP inspection. The company plans to address these findings within the specified timeline, managing potential operational impact.
Dr. Reddy's USFDA inspection at its Mirfield, UK, API facility is officially closed. Outcome classified as 'Voluntary Action Indicated (VAI),' indicating no major issues. This is positive for compliance and operational continuity.
Dr. Reddy's terminated its distribution agreement with Novartis India due to a change in Novartis's shareholding. The company will continue to commercialize the covered brands until September 30, 2026, ensuring a smooth transition.